MedTrace Logo

Safety and Efficacy of Vilazodone in Major Depressive Disorder

NCT01573598 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1219

Last updated 2015-05-18

No results posted yet for this study

Summary

Safety and Efficacy of Vilazodone in Major Depressive Disorder

Conditions

Interventions

DRUG

Placebo

Matching placebo given orally, once per day

DRUG

Vilazodone

Vilazodone, 20 mg per day, oral administration

DRUG

Vilazodone

Vilazodone, 40 mg once per day, oral administration

Sponsors & Collaborators

  • Forest Laboratories

    lead INDUSTRY

Principal Investigators

  • Carrie Reichley · Forest Research Institute, a subsidiary of Actavis plc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2014-10-31
Completion
2015-01-31

Countries

  • United States
  • Bulgaria
  • Finland
  • Germany
  • Romania
  • Russia
  • Serbia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01573598 on ClinicalTrials.gov